[Screening for factor V Leiden mutation in women using combined hormonal contraceptives or hormone replacement therapy].
OBJECTIVE
Analysis of the issue of screening for Factor V Leiden mutation (FVL) in users of combined oral contraceptives (COC) or hormone replacement therapy (HRT).


METHODS
Review article.


METHODS
Department of Obstetrics and Gynecology, Charles University and General Faculty Hospital, Prague.


METHODS
Review of published facts, analysis of possibilities to screen all users or to test risk groups in the current situation in the Czech Republic.


CONCLUSIONS
1) Screening for FVL in all COC or HRT users is not recommended mostly for economical reasons. 2) Testing for FVL is indicated in women with a positive family history of thromboembolic disease and in obese women, if they consider COC or HRT despite our recommendation or in case there is a medical indication. 3) Deep venous thrombosis or pulmonary embolism are absolute contraindications of COC or HRT regardless of the presence of FVL.
Cibula
D
D
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze. david.cibula@oil.cz
Unzeitig
V
V
Zivný
J
J
D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005165:Factor V / Q000235:genetics*; D005260:Female; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D006801:Humans; D017354:Point Mutation; D012307:Risk Factors; D019851:Thrombophilia / Q000175:diagnosis* / Q000235:genetics
D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D005819:Genetic Markers; C095381:factor V Leiden; D005165:Factor V